Literature DB >> 10579969

Polypectomy may be adequate treatment for adenoma-like dysplastic lesions in chronic ulcerative colitis.

M Engelsgjerd1, F A Farraye, R D Odze.   

Abstract

BACKGROUND & AIMS: Chronic ulcerative colitis (CUC)-associated adenoma-like DALMs (dysplasia-associated lesions or masses) pose a difficult clinical problem to both gastroenterologists and pathologists because they are difficult to distinguish endoscopically and pathologically from sporadic adenomas that develop coincidentally in patients with CUC. The aim of this study was to evaluate the outcome of CUC patients with an adenoma-like DALM treated conservatively and to compare the findings with CUC patients with a coincidental sporadic adenoma.
METHODS: Clinical, endoscopic, and pathological features and outcome of 24 CUC patients with an adenoma-like DALM were compared with those of 10 CUC patients with a coincidental sporadic adenoma and 49 non-CUC (control) patients with a sporadic adenoma. Patients were followed up for a mean of 42.4 and 41.2 months for the 2 CUC groups, respectively, and 37.0 months for the non-CUC controls by endoscopic surveillance.
RESULTS: Of the 24 CUC patients with adenoma-like DALMs (male/female ratio, 14/10; mean age, 61.5 years; mean duration of colitis, 10.4 years), 14 (58%) developed further adenoma-like DALMs within the follow-up interval. Only 1 patient (4%) developed an isolated focus of low-grade dysplasia, and none developed adenocarcinoma. Five of 10 (50%) CUC patients with sporadic adenomas developed further adenomas, and none of the patients in this group developed either dysplasia or adenocarcinoma. Of the 49 non-CUC control patients, 39% developed further adenomas.
CONCLUSIONS: CUC patients who develop an adenoma-like DALM that endoscopically and histologically resembles a sporadic adenoma, regardless of its location (either within or outside areas of documented colitis), may be treated with polypectomy and endoscopic surveillance because of its relatively benign course.

Entities:  

Mesh:

Year:  1999        PMID: 10579969     DOI: 10.1016/s0016-5085(99)70278-7

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  46 in total

Review 1.  Diagnostic methodologies: serology, endoscopy, and radiology.

Authors:  T Dassopoulos
Journal:  Curr Gastroenterol Rep       Date:  2001-12

2.  Endoscopic Therapy for Inflammatory Bowel Disease.

Authors:  Eric S. Goldstein; Peter H. Rubin
Journal:  Curr Treat Options Gastroenterol       Date:  2003-06

3.  Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease.

Authors:  J A Eaden; J F Mayberry
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

4.  Surveillance of dysplasia in inflammatory bowel disease: The gastroenterologist-pathologist partnership.

Authors:  David T Rubin; Jerrold R Turner
Journal:  Clin Gastroenterol Hepatol       Date:  2006-11       Impact factor: 11.382

5.  Distal adenomatous polyps are rare in patients with inflammatory bowel disease.

Authors:  A Dixon; P Wurm; A Hart; R Robinson
Journal:  Postgrad Med J       Date:  2006-01       Impact factor: 2.401

Review 6.  Dysplasia and colitis.

Authors:  Robert Enns; Brian Bressler
Journal:  Can J Gastroenterol       Date:  2009-05       Impact factor: 3.522

7.  The cancer "fear" in IBD patients: is it still REAL?

Authors:  T M Connelly; W A Koltun
Journal:  J Gastrointest Surg       Date:  2013-09-04       Impact factor: 3.452

Review 8.  Endoscopic and pathological aspects of colitis-associated dysplasia.

Authors:  Fiona D M van Schaik; G Johan A Offerhaus; Marguerite E I Schipper; Peter D Siersema; Frank P Vleggaar; Bas Oldenburg
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-09-22       Impact factor: 46.802

Review 9.  Colorectal cancer in inflammatory bowel disease: review of the evidence.

Authors:  D S Keller; A Windsor; R Cohen; M Chand
Journal:  Tech Coloproctol       Date:  2019-01-30       Impact factor: 3.781

Review 10.  Cancer in inflammatory bowel disease.

Authors:  Jianlin Xie; Steven H Itzkowitz
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.